drugset / Trial / NCT00495378

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

NCT00495378

Phase 4 Terminated 25 enrolled Ortho Biotech Products, L.P.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to determine if alternate dosing of Epoetin alfa was effective in maintaining hemoglobin levels in patients with chemotherapy related anemia.

Timeline

Start
2002-11
Primary completion
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic Subcutaneous

Indications